+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gazyva

  • ID: 4775410
  • Report
  • 40 pages
  • Datamonitor Healthcare
1 of 3

FEATURED COMPANIES

  • Biogen
  • Chugai
  • Nippon Shinyaku
  • Roche
  • Teva
  • Zenyaku Kogyo
  • MORE

Drug Overview
Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope of the CD20 antigen expressed on the surface of pre-B and mature-B lymphocytes. Gazyva mediates B-cell lysis through engagement of immune effector cells, by direct cell death, and by activation of the complement cascade. Due to its reduced fucose content, Gazyva exhibits increased antibody-dependent cellular cytotoxicity than Rituxan (rituximab; Roche/Biogen/Chugai/Zenyaku Kogyo) in vitro in human cancer cell lines, and improves survival in xenograft models of diffuse large B-cell lymphoma and mantle cell lymphoma. As opposed to Rituxan, which is a type I anti-CD20 MAb, this third-generation anti-CD20 MAb is a stronger inducer of direct cell death and antibody-dependent cellular cytotoxicity. Type II anti-CD20 MAbs have also demonstrated less dependence on complement-dependent cytotoxicity, which is an immune response that involves a series of proteins known as the complement system. Complement activation by Rituxan has been associated with infusion-related side effects of the drug.

Analyst Outlook
Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) gained approval for the treatment of Rituxan (rituximab; Roche/Biogen/Chugai/Zenyaku Kogyo)-refractory follicular lymphoma (FL) in combination with Treanda (bendamustine; Teva), followed by Gazyva monotherapy, in February 2016. The drug is Roche’s third-generation anti-CD20 monoclonal antibody (MAb), and is positioned as a potential replacement for Rituxan in the FL market. Gazyva will experience greater uptake with an anticipated label expansion into the lucrative first-line treatment setting, but The author believes that the drug’s pricing strategy will be a major determinant for its success. Roche will have to balance the desire to maximize payback on its investment with its need to enhance its market penetration.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biogen
  • Chugai
  • Nippon Shinyaku
  • Roche
  • Teva
  • Zenyaku Kogyo
  • MORE
OVERVIEW
Drug Overview
Product Profiles
Gazyva: Chronic lymphocytic leukemia (CLL)
Gazyva: NHL: Follicular lymphoma (FL)
Gazyva: NHL: Mantle cell lymphoma (MCL)

LIST OF FIGURES
Figure 1: The authors drug assessment summary of Gazyva for CLL
Figure 2: The authors drug assessment summary of Gazyva for CLL
Figure 3: Gazyva sales for CLL across the US and five major EU markets, by country, 2017–26
Figure 4: Gazyva for follicular lymphoma – SWOT analysis
Figure 5: The authors drug assessment summary of Gazyva for follicular lymphoma
Figure 6: The authors drug assessment summary of Gazyva for follicular lymphoma
Figure 7: Gazyva sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 8: Gazyva for mantle cell lymphoma – SWOT analysis

LIST OF TABLES
Table 1: Gazyva drug profile
Table 2: Approval history of Gazyva for CLL in the US, Japan, and five major EU markets
Table 3: Trials of Gazyva for CLL
Table 4: Gazyva for CLL – SWOT analysis
Table 5: Gazyva drug profile
Table 6: Gazyva pivotal trial data in follicular lymphoma
Table 7: Gazyva other clinical trials in follicular lymphoma
Table 8: Gazyva ongoing late-phase clinical trials in follicular lymphoma
Table 9: Gazyva sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Gazyva drug profile
Table 11: Gazyva Phase I/II data in mantle cell lymphoma
Table 12: Gazyva Phase Ib/II trial in mantle cell lymphoma
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Biogen
  • Chugai
  • Nippon Shinyaku
  • Roche
  • Teva
  • Zenyaku Kogyo
Note: Product cover images may vary from those shown
Adroll
adroll